IJDMMS- International Journal for Doctor of Medicine and Medical Students (IJDMMS)

Offer for Students ₹ 999 INR ( offer valid till 31st December 2025)

Article Publish

Preeclampsia and Chronic Kidney Disease (CKD) A Bidirectional Relationship

Authors & Affiliations

1. Veronika Tursunova

2. Mohammad Nadeem

3. Ali Haider

4. Priom Kumar Bharti

5. Dharamraj

6. Rahul Raj Gupta

7. Akash Kanshana

8. Pal Bhoomika

(1. Teacher , International Medical Faculty, Osh State University, Osh, Kyrgyzstan.)

(2,3,4,5,6,7,8 Student, International Medical Faculty, Osh State University, Osh, Kyrgyzstan.)

Abstract

Preeclampsia (PE) and chronic kidney disease (CKD) interact through a complex, bidirectional relationship predating CKD increases the danger of gestation- related hypertensive diseases (including superimposed preeclampsia), while preeclampsia is progressively found as a danger label and feasible accelerator for after CKD and end- stage kidney disease (ESKD). This retrospect synthesizes recent epidemiology, offered pathophysiologic mechanisms (placental antiangiogenic state, endothelial dysfunction, and unmasked renal susceptibility), individual complaints, biomarkers (sFlt- 1/ PlGF, NGAL), gestation and postpartum care recommendations, and knowledge breaches. Drawing on coexisting guidelines and cohort/ meta-analytic data, we suggest a realistic clinical route featuring prepossession assessment, prenatal threat estate (involving aspirin prophylaxis where denoted), close monitoring of renal function and proteinuria, multidisciplinary carefulness, and structured postpartum succeed- up to discover patient renal impairment. Research precedences involve standardized definitions, prospective examinations of long- term renal aftereffects, and trials of targeted precluding strategies.

Introduction

Preeclampsia is a multisystem hypertensive sickness of gestation, classically traced as new- onset hypertension (≥ 140/90 mmHg) after 20 weeks’ pregnancy accompanied by proteinuria or other end- organ dysfunction (e.g., renal insufficiency, liver involvement) (Magee et al., 2018). Chronic kidney disease, delineated by pertinacious markers of kidney damage (e.g., albuminuria) or downgraded assessed glomerular filtration rate (eGFR60 mL/min/1.73 m²) for ≥3 months, affects females of reproductive period worldwide and confers accelerated mother and perinatal troubles (KDIGO, 2024). The interplay between PE and CKD is clinically consequential CKD is a recognized strong danger agent for preeclampsia and counter perinatal aftereffects (Jeyaraman et al., 2024), and again, preeclampsia has been associated with advanced risks of coming CKD and ESKD (Vikse et al., 2008; Srialluri et al., 2023). concluding this bidirectional association is essential to optimize carefulness before, during, and after gestation.

Methods

A narrative proof composite was accomplished fastening on literature from 2008 – 2025, prioritizing systematized reviews, meta- analyses, clinical trial guidelines, grand cohort studies, and recent first exploration. Databases and resources searched contained PubMed/ PMC, KDIGO reports, ACOG trial bulletins, NICE guidance, ISSHP accounts, the International Society of Nephrology (ISN) toolkit, and substantial peer- examined journals (AJKD, Kidney International, BJOG, AJOG, Lancet). crucial search terms included “preeclampsia AND habitual kidney disease,” “preeclampsia long- term kidney issues,” “CKD gestation aftereffects,” “sFlt- 1 PlGF preeclampsia,” and “preeclampsia postpartum renal function.” Priority was given to systematized reviews meta- analyses and guideline accounts to insure a guideline- grounded path. When applicable, individual cohort and mechanistic examinations were included to exemplify specific points.

Results

Multiple methodical reconsiderations and great population cohorts establish that women with preexisting CKD expression mainly progressive qualities of preeclampsia, preterm birth, small- for-childbearing- age neonates and cesarean delivery (Jeyaraman et al., 2024; Kanasaki & associates, 2024). Again, a raising body of proof indicates that preeclampsia is associated with accelerated long- term risks of CKD and ESKD meta- logical estimates vary, but numerous studies report around 2 – 4 × advanced risk of subsequent CKD and indeed advanced relative threats for ESKD in women with severe or early- onset PE (Vikse et al., 2008; Covella et al., 2019; Srialluri et al., 2023). Population cohorts beyond suggest that early- onset or intermittent PE confers the topmost long- term renal risk. Pathophysiology — mechanisms relating PE and CKD

The association appears multifactorial Preexisting renal susceptibility females with unknown CKD (e.g., low- grade proteinuria, downgraded eGFR) have disrated renal reserve, forming them more susceptible to the hemodynamic and endothelial stresses of gestation, boosting the chance of superimposed PE (ISN toolkit; KDIGO).

Placental antiangiogenic state Preeclampsia is defined by accelerated antiangiogenic factors (solvable fms-like tyrosine kinase- 1, sFlt- 1) and diminished placental growth factor (PlGF), producing systemic endothelial dysfunction — a medium that can acutely break glomerular endothelium and podocytes and produce proteinuria and degraded GFR (Chen et al., 2024; multiple reviews).

Inflammation & vulnerable mechanisms Aberrant placentation, complement activation and seditious cytokines contribute to glomerular injury. In susceptible individualities(e.g., underpinning glomerulopathy, autoimmunity), gestation may conclusion clinical deterioration.

Revealing vs creative injury, A crucial abstract point is that PE may “unmask” ahead conceal CKD (proteinuria or broke eGFR that predates gravidity) versus directly causing endless kidney injury. patient proteinuria or bloodied renal function beyond 3- 6 months postpartum suggests underlying CKD rather than flash PE- related changes (KDIGO; NICE).

Diagnostic challenges & biomarkers

secerning true preeclampsia from CKD flare or superimposed preeclampsia is clinically grueling because both present with hypertension and proteinuria. Strategies to ameliorate demarcation include: Clinical history & preconception data genesis urine ACR/ PCR and serum creatinine before or prematurely in gestation are inestimable (KDIGO; ISN).

sFlt- 1/ PlGF rate the sFlt- 1/ PlGF rate is helpful for governing out preterm PE and prognosticating counter short- term issues; incorporating it into latterly childbearing assessments can assist decision- making (NICE DG49; Chen et al., 2024). While promising, service in cases with known CKD requires conservative interpretation.

Urine ACR/ PCR & current monitoring Quantifying proteinuria (ACR/ PCR) rather than counting on dipstick alone is recommended by contemporary guidelines (NICE). patient proteinuria postpartum clearances nephrology evaluation.

Maternal & fetal Problems in CKD Pregnancy

aftereffects worsen with advancing CKD stage. Women with CKD experience advanced rates of preeclampsia (including early- onset), preterm birth, fetal growth restriction, and neonatal ferocious care admission; motherly hazards include worsening renal function and need for dialysis in advanced illness (Jeyaraman et al., 2024; Lihme et al., 2025). Strategies that alleviate threat include prejudgment optimization, tight BP control with gestation-safe antihypertensives (e.g., labetalol, nifedipine, methyldopa), and multidisciplinary prenatal care.Clinical Relevance / Commen

Prevention & prenatal care

Aspirin prophylaxis Low- dosage aspirin (generally 75 – 150 mg/ day or 81 mg in US counsel) is recommended for women at high threat of preeclampsia, a group that includes those with CKD or a history of PE (USPSTF, ACOG, NICE). Beforehand inauguration (before 16 weeks in numerous guidelines) optimizes benefit.

Blood pressure targets & specifics Antihypertensive remedy in gestation aims to limit severe hypertension and optimize fetal aftereffects; recommended agents include labetalol, nifedipine, and methyldopa; ACE inhibitors and ARBs are contraindicated due to teratogenicity. The choice and timing must balance motherly renal protection and fetal safety (ACOG; KDIGO summaries).

Surveillance Frequent BP checks, periodical growth reviews, proteinuria quantification, and renal function tests are recommended. Use of sFlt- 1/ PlGF testing in suspected early preeclampsia helps risk estate (NICE).

Postpartum follow- up & long- term renal risk

Women with preeclampsia should have structured postpartum evaluation because patient hypertension, proteinuria, or reduced eGFR may indicate habitual kidney disease (NICE; KDIGO). Cohort data link PE with increased future CKD and ESKD threat; topmost threat is seen after early- onset, periodic, or severe PE (Srialluri et al., 2023; Haudiquet et al., 2025). Recommendations include BP monitoring, serum creatinine/ eGFR and urine ACR assessment at 6 – 12 weeks postpartum and continued long- term cardiovascular and renal guidance where indicated.

Discussion

Grounded on the substantiation, a realistic clinical pathway for women with CKD or previous preeclampsia includes:

Preconception assess renal function(eGFR), urine ACR/ PCR, BP control, review specifics (cease ACEi/ ARB and teratogenic immunosuppressants), counsel about threats, and plan aspirin if indicated. prematurely nephrology/ obstetric coordination is counseled (KDIGO; ISN).

prenatal early booking (<10 weeks), baseline renal tests, individualized surveillance frequency (based on CKD stage), low-dose aspirin for high-risk women, and use of pregnancy-safe antihypertensives.

Conclusion

Preeclampsia and habitual kidney disease share a bidirectional relationship CKD increases the threat of preeclampsia and counter perinatal aftereffects, while preeclampsia — especially when early, severe, or periodic — predicts advanced long- term threats of CKD and ESKD. Clinicians should borrow a lifecycle approach prepossession optimization, targeted prenatal surveillance (including aspirin prophylaxis and picky biomarker use), multidisciplinary governance during gravidity, and structured postpartum assessment to determine insistent renal disease and institute long- term preventative care. unborn exploration should concentrate on mechanistic explanation, biomarker documentation in CKD populations, and interventions to help long- term renal threat.

References

1.ACOG. (2020). Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia. American College of Obstetricians and Gynecologists.

2.Barrett, P. M., et al. (2020). Hypertensive disorders of pregnancy and long-term maternal kidney disease: systematic review. Journal/PMC.

3.Chen, G., et al. (2024). A dynamic prediction model for preeclampsia using the sFlt-1/PlGF ratio. Journal/PMC.

4.Crump, C., et al. (2024). Adverse pregnancy outcomes and long-term risk of chronic kidney disease. AJOG.

5.Covella, B., Vinturache, A. E., Cabiddu, G., et al. (2019). Long-term risk of CKD after preeclampsia: systematic review and meta-analysis. Kidney International.

6.Haudiquet, M., et al. (2025). A systematic review on determinants of long-term kidney disease after preeclampsia. Acta Obstet Gynecol Scand.

7.Jeyaraman, D., Walters, B., Bramham, K., Fish, R., Lambie, M., & Wu, P. (2024). Adverse pregnancy outcomes in pregnant women with chronic kidney disease: systematic review and meta-analysis. BJOG.

8.KDIGO. (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int.

9.Kanasaki, K., et al. (2024). Risk of preeclampsia in pregnant individuals with chronic kidney disease. Hypertension Research / Nature.

10.Lailler, G., et al. (2024). Early mortality, cardiovascular, and renal diseases after preeclampsia: systematic review. JAHA.

11.Lihme, I., et al. (2025). Nationwide register-based cohort: maternal preeclampsia and kidney disease. Kidney International.

12.Magee, L. A., et al. (2018). ISSHP classification and guidance on hypertensive disorders of pregnancy. ISSHP.

13.Mol, B. W., Roberts, C. T., Thangaratinam, S., et al. (2016). Preeclampsia. The Lancet, 387(10022), 999–1011.

14.Newman, C., et al. (2024). Hypertension and preeclampsia in pregnancy: review. Journal/PMC.

15.NICE. (2019; updated 2023). Hypertension in pregnancy: diagnosis and management (NG133). National Institute for Health and Care Excellence.

16.Preeclampsia Foundation/WHO summary. (2025). Pre-eclampsia fact sheet. World Health Organization.

17.Srialluri, N., et al. (2023). Preeclampsia and long-term kidney outcomes. AJKD/PMC.

18.Sharma, D. D., et al. (2024). The management of preeclampsia: a comprehensive review. Journal/PMC.

19.Vikse, B. E., Irgens, L. M., Leivestad, T., Skjaerven, R., & Iversen, B. M. (2008). Preeclampsia and risk of end-stage renal disease. NEJM, 359, 800–809.

20.WHO. (2025). Pre-eclampsia fact sheet. World Health Organization.

21.Zhang, L., et al. (2025). Predictive performance of sFlt-1, PlGF and their ratio for preeclampsia: systematic review. Journal.

22.De Oliveira, L., et al. (2024). Magnesium sulfate in preeclampsia: indications and outcomes. Review.

23.USPSTF. (2021). Low-dose aspirin to prevent preeclampsia: recommendation statement. JAMA.

24.Davidson, K. W., et al. (2021). Aspirin use during pregnancy systematic review & guidance (USPSTF). JAMA.

25.ISN. (n.d.). Pregnancy and Kidney Disease Toolkit. International Society of Nephrology.

26.Marek-Iannucci, S., et al. (2023). Association of chronic kidney dysfunction and preeclampsia. Journal.

27.Piccoli, G. B., et al. (2025). Women and kidney health: conclusions from a global conference. Journal.

28.Wu, W., et al. (2024). Association between preterm delivery and risk of chronic kidney disease: meta-analysis. Experimental and Therapeutic Medicine.

29.Karger/AJN 2025 (recent): Preeclampsia and onset of renal disorders in the long term. Article.

30.Srialluri, N., et al. (2024). Call for early nephrology referral and multidisciplinary care in pregnancy complicated by renal disease. Article/PMC.

Back

Google Sites

Report abuse